Carson Block of Muddy Waters Capital makes the short case on Chinook Therapeutics (KDNY). Muddy Waters argues that, upon further examination of trial data, its primary candidate for kidney disease, atrasentan, not only is inefficacious, but also shows an alarming rate of patient heart failure.
At long last, the man at the heart of the Kenyan chess scandal has been brought to justice! Freddy, never one to put too much effort into his footwear, finds it comical that the size-11 sneakers weren’t spotted beneath the burka. The real question comes from whether it’s necessary to separate men and women for chess tournaments. Bodybuilding competitions? Absolutely. But chess? Perhaps the answer lies with Matt Moulding who is eager to lend a hand with some of his protein.
Soren Aandahl of Blue Orca Capital makes the short case on Shift4 (FOUR). Blue Orca argues that the Company’s gross profit, EBITDA, and cash flow are inflated by a series of hyper-aggressive maneuvers undertaken just as the decline in FOUR’s share price created the threat of a margin call on its CEO’s equity-backed loan.
Recent Comments